DiaMedica Therapeutics (NASDAQ: DMAC) — Perfil da empresa, notícias e dados financeiros
DiaMedica Therapeutics focuses on novel therapies for chronic kidney disease and neurological disorders, advancing DM199.
DiaMedica Therapeutics
DiaMedica Therapeutics (NASDAQ:DMAC) is a biopharmaceutical company focused on the discovery and development of novel therapies for patients suffering from chronic kidney disease and neurological disorders, aiming to address unmet medical needs in these areas. Currently, DiaMedica is traded on the NASDAQ stock exchange under the ticker symbol DMAC. The company is dedicated to advancing its lead product candidate, DM199, through clinical trials. This recombinant human protein aims to treat a range of conditions, from acute ischemic stroke to chronic kidney diseases, by leveraging its potential to improve blood flow and kidney function. DiaMedica's objective is to deliver innovative treatments that can significantly improve patients' quality of life and outcomes in areas where current options are limited or nonexistent.
Resumo
Operações
Produtos e/ou serviços de DiaMedica Therapeutics
- DM199, a recombinant human tissue kallikrein-1 for treating acute ischemic stroke and chronic kidney disease, aiming to improve outcomes by impacting underlying disease mechanisms.
- Chronic Kidney Disease program, focusing on improving kidney function and slowing progression through innovative therapies, targeting an unmet medical need in nephrology.
- Acute Ischemic Stroke Treatment, a breakthrough approach leveraging DM199 to potentially enhance recovery and reduce disabilities by restoring blood flow and protecting brain tissue.
- Clinical Trials Management, dedicated to advancing research in neurological and kidney diseases through well-designed, rigorous clinical studies, ensuring safety and efficacy of therapies.
- Kidney Health Research, centered on the development of novel diagnostics and treatments to address the early detection and management of kidney diseases.
- Collaborative Research Initiatives, fostering partnerships with academic and medical institutions to accelerate the discovery and development of therapeutic solutions.
equipe executiva do DiaMedica Therapeutics
- Dietrich John PaulsPresident, CEO & Director
- Scott KellenCFO & Corporate Secretary
- Julie KropChief Medical Officer
- Ambarish ShahChief Technology Officer
- Dominic R. CundariChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela DiaMedica Therapeutics, em USD.
- Cap. de mercado
- 529,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -34,4 mi | -32,8 mi | |
| 0 | -26,7 mi | -24,4 mi | |
| 0 | -21,3 mi | -19,4 mi | |
| 0 | -14 mi | -13,7 mi |